Important US business magazine, Forbes, has crafted a list of the 100 most innovative companies on which the Danish medtech and pharma industry features prominently.
Coloplast makes it to number 12, and further down the list at number 70 diabetes giant Novo Nordisk is found.
The list is based on a so-called innovation premium, defined as “a measure of how much investors have bid up the stock price of a company above the value of its existing business based on expectations of future innovative results (new products, services and markets),” the magazine writes.
Moreover, companies on the list must have $10 billion in market capitalization, spend at least 2.5% of revenue on R&D and have seven years of public data.
In this regard, Coloplast and Novo scores an innovation premium of 46,5 % and 23,4 % respectively.
Life science fairs well
Generally speaking, the life science industry fairs well on Forbes’ innovation list. Two biotech companies, Alexion Pharmaceuticals (2) and Regeneron Pharmaceuticals (4), make it into the top 5.
Further down the list the medtech and pharmaceutical industries are represented by major corporations like Smith & Nephew (51), Valeant Pharmaceuticals (62), Covidien (67) og Mylan (90).
The only other Danish company on the list aside from Coloplast and Novo is Carlsberg, which slots in at 66.
See the complete list from Forbes here.
Want to receive the latest news from Medwatch straight in your e-mail inbox? Sign up for our free english newsletter below.
Mere fra MedWatch
Københavns Universitet har indledt jagten på den programdirektør, der skal stå i spidsen for innovationsprogrammet Spark Denmark, som Novo Nordisk Fonden forleden kastede 44 mio. kr. efter for at bringe flere akademiske projekter indenfor farma, medico, sundhedsteknologi og industriel biotek til markedet.